187 related articles for article (PubMed ID: 18262363)
1. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel in the treatment of advanced urothelial cancer.
Bajorin DF
Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced bladder cancer in patients with impaired renal function.
Bournakis E; Dimopoulos MA; Bamias A
Expert Rev Anticancer Ther; 2011 Jun; 11(6):931-9. PubMed ID: 21707290
[TBL] [Abstract][Full Text] [Related]
4. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
Culine S
Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
[No Abstract] [Full Text] [Related]
6. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
7. Systemic chemotherapy options for metastatic bladder cancer.
Siefker-Radtke A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):877-85. PubMed ID: 16761931
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
9. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.
Kastritis E; Dimopoulos MA; Antoniou N; Deliveliotis C; Chrisofos M; Skolarikos A; Gika D; Bamias A
Anticancer Res; 2006; 26(5B):3865-9. PubMed ID: 17094415
[TBL] [Abstract][Full Text] [Related]
10. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
Dreicer R; Roth B; Wilding G;
Cancer; 2003 Apr; 97(8 Suppl):2109-14. PubMed ID: 12673703
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
13. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M; Bachner M
Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
[TBL] [Abstract][Full Text] [Related]
14. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
Sonpavde G; Galsky MD; Vogelzang NJ
J Clin Oncol; 2010 Sep; 28(25):e441-2; author reply e443-4. PubMed ID: 20644092
[No Abstract] [Full Text] [Related]
15. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
17. Nonplatinum therapy in advanced bladder cancer.
Srinivas S; Colocci N
Expert Rev Anticancer Ther; 2006 Jun; 6(6):887-94. PubMed ID: 16761932
[TBL] [Abstract][Full Text] [Related]
18. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for muscle-invasive and advanced urothelial cancer.
Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
